Abstract:Paul Ganguly College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia Correspondence: Paul Ganguly, College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia, Tel +966503092964, Email The past several decades have shown the functional status of sympathetic activity in congestive heart failure. The results, particularly through clinical and basic studies in heart failure, indicate an increased sympathetic neural activity. The definitive and compelling evidence of the involvement of catecholamines is the demonstration that many drugs that are therapeutically useful in the treatment of heart failure also affect the sympathetic nervous system at various sites, including its synthesis, release and uptake of catecholamines and a decreased plasma norepinephrine level. Although it is not surprising that the sympathetic system is altered as cardiac function is compromised in heart failure, it now appears that this system may overreact in chronic situations. The detrimental cardiovascular problems result in the production of aminochrome and free radicals. Antioxidant therapy to target the production of aminochrome from autooxidation of catecholamines should provide an insight into the future therapeutic goal in situations like congestive heart failure. Keywords: aminochrome, congestive heart failure, antioxidants, cardiac dysfunction, intracellular mechanisms Heart failure can be defined as a condition of decreased cardiac function to maintain systemic circulation appropriate to the body's need under physiological conditions or during increased demand, and is often associated with irregular heart rate, enlarged heart, ischemia, and cell death. Despite advances in understanding of the pathophysiology and treatment, heart failure continues to be a challenge in the scientific community as it is a major cause of morbidity and mortality worldwide. Proven through a variety of molecular approaches for studying human sympathetic neural function, many studies have now shown that the activation of the sympathetic nervous system is a hallmark of congestive heart failure. 1,2 Heart failure is associated with an initial decrease in pumping capacity of the heart. During this time, a variety of compensatory mechanisms are activated, including the adrenergic nervous system, the renin-angiotensin system, and the cytokine system. In the short term these systems allow the restoration of cardiovascular function to a normal homeostatic range, with the result that the patient may remain free from major symptoms. However, over time the chronic activation of these systems can lead to secondary end-organ damage within the ventricle and subsequent cardiac dysfunction with decreased cardiac contractility. As a result of the worsening of cardiac decompensation, patients go from asymptomatic to symptomatic heart failure. In particular, the adrenergic overdrive in heart failure is associated with effector organs, such as the downregulation of beta-receptors at the cardiac level which exerts negatively on the cardiovascular system. 1,2 Defective sodium-calcium exchange can also contribute to the contractility of the heart. Given the fact that heart failure and sympathetic activation are closely related, the adrenergic overdrive has become a target of therapeutic interventions. 3 The purpose of this article is to summarise the fact that; a) sympathetic activity is increased in congestive heart failure, b) oxidant and free radical species have been involved and c) newer antioxidants specially targeting molecules such as aminochrome derived from heightened sympathetic activity are the future therapeutic goal in this disease. There are many published reports 4,5 indicating the heightened sympathetic tone in patients with congestive heart failure and provided evidence that there is a direct correlation between plasma norepinephrine and prognosis of the disease. Heightened sympathetic activity has been proposed to play a major role in the progression of the disease and outcome through its effect on myocardial cells, arrhythmia, and possible excitation-contraction coupling. 1,2 Most patients with heart failure show increased sympathetic activity as evidenced from increased plasma norepinephrine levels either in rest or during exercise. However, in spite of higher plasma norepinephrine levels, the heart rate of these patients was not increased, and signs of vasoconstriction werre not evident. Such observations clearly indicate that some adaptation to prolonged sympathetic activity occurs. In fact, the response of failing hearts to both exogenous and endogenous catecholamines become markedly attenuated. It has been suggested that the down regulation of beta-adrenergic receptors is primarily responsible for such an effect. 1,2 Other studies have shown that -Abstract Truncated-

Increased Systemic Inflammation And Oxidative Stress In Patients With Worsening Congestive Heart Failure: Improvement After Short-Term Inotropic Support

Abstract 399: End-stage Heart Failure Causes Severe Lung Fibrosis and Dysfunction

The relationship between cardiac oxidative stress, inflammatory cytokine response, cardiac pump function, and prognosis post-myocardial infarction

Dobutamine in the Management of Advanced Heart Failure

Increased neutrophil lifespan in patients with congestive heart failure

Interplay between Pro-inflammatory Mediators and Oxidative Stressinvolved Recurrent Chronic Heart Failure in Elderly Patients with Coronary Stents

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

Guideline-Optimised Treatment in Heart Failure—Do Higher Doses Reduce Systemic Inflammation More Significantly?

Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in heart failure patients

Impact of congestive heart failure treatment on peripheral microvascular tissue oxygenation

Possibility of Inhibition of TNF-α/NF-kB Signaling Pathway Activation in Myocardium and Reverse Cardiac Hemodynamics in Chronic Ischemic Heart Disease

Chronic activation of hypothalamic oxytocin neurons improves cardiac function during left ventricular hypertrophy-induced heart failure

Dynamic molecular and histopathological changes in the extracellular matrix and inflammation in the transition to heart failure in isolated volume overload.

[Peripheral adaptation in chronic heart failure: therapeutic implications]

Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy‐induced ventricular remodelling and dysfunction

Nutritional Support Reduces Circulating Cytokines in Patients with Heart Failure

Abstract 13438: The Role and Mechanism of Chronic Beta3-Adrenergic Receptor Blockade on the Progression of Heart Failure in a Rat Model

Outpatient Continuous Intravenous Inotropy in the Modern Era

Effects Of Low Level Tragus Stimulation On Inflammation In Acute Decompensated Heart Failure

Oxidative Products of Catecholamines During Heightened Sympathetic Activity Due to Congestive Heart Failure: Possible Role of Antioxidants

The Changes of Circulating Tumor Necrosis Factor Levels in Patients with Congestive Heart Failure Influenced by Therapy.